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Abstract
Background: The highest incidence of rotavirus gastroenteritis has generally been reported in children 6-24 months of 
age. Young infants are thought to be partially protected by maternal antibodies acquired transplacentally or via breast 
milk. The purpose of our study was to assess the age distribution of children with confirmed community-acquired 
rotavirus gastroenteritis presenting to an urban referral hospital.
Methods: Children presenting to The Children's Hospital of Philadelphia with acute gastroenteritis have been 
monitored for the presence of rotavirus antigen in the stool by ELISA (followed by genotyping if ELISA-positive) since 
the 1994-95 epidemic season.
Results: Over the last 12 rotavirus seasons prior to the introduction of the pentavalent rotavirus vaccine in 2006, stool 
specimens from 1646 patients tested positive for community-acquired rotavirus infection. Gender or age was not 
recorded in 6 and 5 cases, respectively. Overall, 58% of the cases occurred in boys. G1 was the predominant VP7 
serotype, accounting for 72% of cases. The median (IQR) age was 11 (5-21) months. A total of 790 (48%) cases occurred 
in children outside the commonly quoted peak age range, with 27% in infants <6 months of age and 21% in children 
>24 months of age. A total of 220 (13%) cases occurred during the first 3 months of life, and the highest number of 
episodes per month of age [97 (6%)] was observed during the second month of life.
Conclusions: The incidence of community-acquired rotavirus gastroenteritis monitored over 12 seasons in the 
prevaccine era at a major university hospital was nearly constant for each month of age during the first year of life, 
revealing an unexpectedly high incidence of symptomatic rotavirus disease in infants <3 months old. A sizeable 
fraction of cases occurred in children too young to have been vaccinated according to current recommendations.
Background
In the absence of a safe and effective vaccine (1-3), rotavi-
rus has consistently been the leading cause of dehydrating
gastroenteritis in infants and young children around the
world (4-20). Virtually all children are infected at least
once within the first 5 years of life, with the peak inci-
dence widely quoted as occurring between 6 and 24
months of age (5, 7, 11, 13, 14, 16, 20-23). For the first few
months of life, infants are thought to be partially pro-
tected by maternal antibodies acquired transplacentally
or through breast feeding (24-26). The Advisory Com-
mittee on Immunization Practices currently recommends
the initiation of the rotavirus vaccine series at 2 months
of age, although the first dose can be given as early as age
6 weeks (27, 28). If infants during the first few months of
life are at greater risk for symptomatic rotavirus infection
than has been generally appreciated, routine immuniza-
tion schedules might be reconsidered in order to extend
the benefits of rotavirus vaccine to these vulnerable
infants. Of course, the safety, effectiveness, and feasibility
of immunizing neonates would have to be established.
We examined the age distribution of children presenting
to The Children's Hospital of Philadelphia (CHOP) with
community-acquired rotavirus gastroenteritis prior to
the recent introduction of the new rotavirus vaccines to
assess the burden of rotavirus infection serious enough to
motivate hospital visits in neonates and young infants.
Methods
The surveillance protocol was approved by the institu-
tional review board at CHOP (1, 29, 30). Informed con-
sent from legal guardians was not required to procure
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and process stool specimens already obtained from chil-
dren with acute gastroenteritis as part of standard clinical
practice. Based on prior experience, the rotavirus epi-
demic season in Philadelphia was defined as the seven-
month period from December 1 through June 30 of the
following year (1, 29, 31). For 14 consecutive rotavirus
seasons (1994-95 to 2007-08), all patients (regardless of
age) presenting to CHOP with acute gastroenteritis and
having an adequate stool sample were tested by a com-
mercial qualitative enzyme-linked immunosorbent assay
(ELISA) for rotavirus antigen (Premier Rotaclone, Merid-
ian Bioscience, Cincinnati, OH).
For the first 5 rotavirus seasons studied (1994-95 to
1998-99), a subset of ELISA-positive clinical samples
were analyzed at the Centers for Disease Control (CDC)
as part of a national surveillance program. Viruses of
identical electropherotype to our samples serotyped at
the CDC were considered the same as the reference type
(32). Beginning with the 1999-2000 season, ELISA-posi-
tive specimens were submitted to Merck Research Labo-
ratories (MRL) for genotyping by reverse transcriptase-
polymerase chain reaction (RT-PCR) if the quantity of the
stool sample permitted. For the MRL analysis, a 365-bp
RT-PCR product targeting the VP7 gene was amplified
from isolated RNA and subsequently sequenced (33).
Designation of G-type was based on nucleic acid homol-
ogy in comparison with a database of sequences of known
serotypes.
For the present analysis, only community-acquired
cases during the last 12 rotavirus seasons prior to the
introduction of the pentavalent rotavirus vaccine (RV5;
RotaTeq, Merck, Whitehouse Station, NJ, USA) in 2006
were analyzed. A monovalent rotavirus vaccine (RV1;
Rotarix, GlaxoSmithKline Biologicals, Rixensart, Bel-
gium) was approved in April 2008. A tetravalent vaccine
(Rotashield, Wyeth, Collegeville, PA, USA) had been tem-
porarily available in the United States in 1998-99 before
being withdrawn from the market because of the risk of
intussusception. Families seeking care at CHOP resided
for the most part in Philadelphia or its immediately sur-
rounding suburbs (34). Hospital-acquired infections,
defined as developing >48 hours after admission or <48
hours after discharge, were excluded. Nosocomial infec-
tions had constituted ~20% of the total number of rotavi-
rus cases diagnosed at CHOP in the pre-RV5 era (30). For
each season and for all twelve seasons combined, the
median (interquartile range [ I Q R ] )  a g e  i n  m o n t h s  w a s
calculated for children presenting to CHOP with commu-
nity-acquired rotavirus gastroenteritis.
Results
A total of 1646 unique community-acquired cases of
rotavirus gastroenteritis were identified during 12 sea-
sons from 1994-95 to 2005-06 (Table 1). Gender or age
was not recorded in 6 and 5 cases, respectively. There
were a higher percentage of boys than girls in each sea-
son, and overall there were 58% (n = 947) male cases and
42% (n = 693) female cases in the combined 12 monitored
seasons (excluding the 6 cases where the gender was not
recorded). The race for the majority of children when
known was non-white. The predominant serotype was
G1 (ranging from 41%-97%); however, the 1994-95 season
had a high percentage of G3 cases (93%), the 1995-96 and
1999-2000 seasons had a high percentage of G9 cases
(52% and 41%, respectively,) and the 2005-2006 season
had a high percentage of G2 cases (39%).
The median [IQR] age for the 1641 evaluable cases over
the combined 12 rotavirus epidemic seasons prior to the
availability of RV5 was 11 [5-21] months, with a full range
of 0-240 months (Figure 1). Overall, 48% of children fell
outside the commonly quoted peak age range of 6-24
months, with 27% of cases occurring in infants <6
months of age and 21% of cases occurring in children >24
months of age (Figure 2). A total of 220 (13%) cases
occurred during the first 3 months of life, and the highest
number of episodes per month of age [97 (6%)] were
observed during the second month of life. In contrast to
the prevaccine era, the median age of children presenting
to CHOP with community-acquired rotavirus gastroen-
teritis during the 2007-08 season was 20 months and dur-
ing the 2008-09 season was 23.5 months.
The serotype distribution by age group is displayed in
Table 2. Despite some fluctuation in the predominant cir-
culating serotype in the community, the age distribution
was generally similar for each of the 12 seasons. However,
for the two most common VP7 types, G1 cases occurred
slightly less often in children <6 months of age (63%) than
in older children (>70%), whereas G2 cases occurred
twice as frequently in children during the first 6 months
of life (19%) compared to children during the second 6
months of life (9%). Although the number of cases was
relatively small, G9 rotaviruses were also disproportion-
ately represented in children under the age of 6 months
(11%) versus older children (<7%).
Discussion
Although rotavirus accounts for an estimated half-million
deaths each year in the developing world (17), the public
health burden of rotavirus gastroenteritis in industrial-
ized nations is largely measured in infant morbidity,
healthcare costs, missed daycare, and loss of time from
work for parents/guardians (6, 9, 11, 13, 15, 16, 19, 23, 35,
36). The rotavirus epidemic season in the United States
typically begins in the autumn in the Southwest and
spreads across the country ending in the spring of the fol-
lowing calendar year in the Northeast (31). Rotavirus
infections typically peak in Philadelphia during March
and April (1, 29, 35).Clark et al. BMC Pediatrics 2010, 10:40
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The general consensus dating back to the seminal
r e po rt  o f  a  " r eo vi ru s- l i k e  a g e n t "  as  t h e  m a jo r  ca us e  o f
"winter" gastroenteritis in hospitalized infants and young
children has been that symptomatic rotavirus infections
predominantly afflict children between 6 and 24 months
of age (14). Despite published data to the contrary (4, 9,
10, 15, 37, 38), respected textbooks of infectious diseases
(5, 20) continue to propagate the dogma that rotavirus
gastroenteritis is largely a disease of children older than 6
months of age through their second birthday. Assuming
that the age distribution of the population served by
CHOP is not skewed, we found that the monthly inci-
dence of community-acquired rotavirus cases during the
12 years prior to licensing of RV5 was consistently high
from birth to 12 months of age, followed by a marked and
sustained decline in children older than 1 year. By com-
piling incidence data for individual months of age rather
than for clusters, a high rotavirus attack rate was evident
during the first 3 months of life. The highest number of
episodes per month of age was seen among children in
their second month of life. The surprising frequency of
neonatal cases demonstrates that a non-trivial number of
newborns might not be adequately protected by maternal
antibodies (25, 26). The clear excess of rotavirus disease
during the first versus second year of age in our experi-
ence also conflicts with several studies where more rota-
virus disease was reported in the second year rather than
the first year of life (9, 11, 12, 23).
Some differences between our data and earlier reports
are more apparent than real. For example, the benchmark
article by Kapikian et al. identified "reovirus" in stool
specimens by electron microscopy from 60 of 143 tested
Table 1: Demographic characteristics of the 1646 community-acquired cases of rotavirus gastroenteritis presenting to 
CHOP in the pre-vaccine era◊ between the 1994-95 and 2005-06 epidemic seasons
Rotavirus 
season
Number 
of cases
Median age§ 
[IQR] (months)
Predominant 
serotype‡
% male¶ % urban residents % non-white 
race#
1994-1995 178 8
[4 - 16]
G3 61% majority unknown 47%
28% unknown
1995-1996 155 9
[4 - 16]
G9, G2 58% 70% 
5% unknown
78%
2% unknown
1996-1997 115 9
[6 - 17.25]
G1 66% majority unknown 52%
11% unknown
1997-1998 84 11.5
[6 - 24]
G1 55% majority unknown 26%
49% unknown
1998-1999 166 10
[4 - 19.5]
G2, G1 57% majority unknown 59%
11% unknown
1999-2000 94 11
[4.75 - 22]
G1 (47%)
G9 (41%)
53% 66% 67%
2000-2001 115 14
[7 - 22]
G1 (95%) 62% 79% 50%
2001-2002 92 11
[6.25 - 19]
G1 (94%) 58% 44% 58%
2002-2003 29† 11
[5.5 -17]
G1 (97%)† 55% 48% 55%
2003-2004 158 13
[7 - 26.25]
G1 (69%)
G12 (11%)
52% 47% 49%
2004-2005 185 14
[7 - 22]
G1 (87%) 53% 48% 55%
2005-2006 275 11
[5 - 25]
G1 (51%)
G3 (39%)
59% 55% 70%
◊A tetravalent rotavirus vaccine had been transiently available in the United States in 1998-99.
§Age was not recorded for 5 children. The median [IQR] age for the other 1641 children seen at CHOP during the 12 rotavirus epidemic 
seasons combined was 11 (5 - 21) months.
‡From 1994-95 to 1998-99, serotypes were based on electropherotypes compared to CDC standards. Starting with the 1999-2000 season, 
serotypes were determined by RT-PCR genotyping.
¶Excludes 6 children where the gender was not recorded.
#The "non-white" category potentially includes children of African, Asian, Hispanic, Eskimo, and Native American heritage.
†Due to a laboratory accident, only 29 specimens from the 175 cases in the 2002-2003 rotavirus season were suitable for genotyping.Clark et al. BMC Pediatrics 2010, 10:40
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children hospitalized with "winter" gastroenteritis, a not
inconsequential 10 (17%) of whom were <6 months of age
(14). Although the proportion of cases with "reovirus"
identified in stool samples was threefold higher in chil-
dren 6-12 months old [25 of the 39 children tested (64%)]
than in younger infants [10 of the 48 children tested
(21%)] hospitalized in the winter for acute gastroenteritis,
these data are often misconstrued as establishing that
symptomatic rotavirus infection before age 6 months is
rare in an absolute sense. Other seeming inconsistencies
between our findings and previously published data
might be explained by selection and ascertainment
biases, racial and socioeconomic factors, variations in the
circulating serotypes, and/or geographical differences. As
an illustration, for rotavirus gastroenteritis in the United
States, hospitalization of black infants tends to occur on
average at a younger age than hospitalization of white
infants (7, 16). In addition, G2 rotavirus infections at
C H O P  o c c u r r e d  t w i c e  a s  f r e q u e n t l y  i n  c h i l d r e n  < 6
months of age than in children 6-12 months of age. To
further complicate direct comparisons of our results with
prior studies indicating that infection with rotavirus in
young infants requiring a healthcare intervention is not
uncommon (4, 37, 38), some publications do not clearly
distinguish nosocomial from community-acquired acqui-
sition.
The methodological limitations of our analysis should
be acknowledged. We did not directly assess the popula-
tion incidence of severe rotavirus gastroenteritis. Instead,
we used the number of children presenting to CHOP
with acute gastroenteritis associated with a rotavirus-
positive ELISA as our denominator. The index of suspi-
cion for rotavirus infection might be influenced by the
age of the child, and stool specimens may be more or less
l i k e l y  t o  b e  o b t a i n e d  f r o m  d i a p e r e d  b a b i e s  t h a n  o l d e r
children. The age distribution for community-acquired
cases presenting to the hospital may be skewed toward
younger age groups relative to the overall distribution in
the community because infants may be more compro-
mised by gastroenteritis than older children and/or par-
ents may be more likely to seek medical attention for
younger than for older children. Even though our
approach may be confounded by selection bias, the sam-
ple is likely representative of the general population of
Figure 1 Age distribution of the 1641 evaluable community-acquired rotavirus cases presenting to CHOP during the last 12 rotavirus epi-
demic seasons (1994-05 through 2005-06) prior to introduction of the new rotavirus vaccines. A histogram shows the frequency of commu-
nity-acquired rotavirus cases presenting to CHOP by age for the entire 12-year time period under study. Mean age = 18.1 months; standard deviation 
= 25.1 months; minimum age = 0 months; Q1 = 5 months; median age = 11 months; Q3 = 21 months; maximum age = 240 months; IQR = 16 months. 
Age was not recorded for 5 of the 1646 children with community-acquired rotavirus gastroenteritis presenting to CHOP during this period, who were 
therefore excluded from the analysis.
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children sick enough to necessitate a hospital visit for
community-acquired rotavirus infection. While admit-
tedly not definitive, these results indicate a need to re-
examine the conventional wisdom and its implications
for clinical practice as we move forward in the rotavirus
vaccine era.
Conclusions
The peak incidence of serious rotavirus infections is still
generally quoted as occurring in children after 6 months
of age and extending out to 24 months of age (5, 20).
Although true in a cumulative sense, the monthly inci-
dence of community-acquired cases seen at our hospital
was comparable for both halves of the first year of life,
and then dramatically dropped off. Based on 12 rotavirus
seasons monitored at CHOP prior to the introduction of
the recently licensed vaccines, we found a large fraction
(48%) of cases outside the putative peak age range of 6-24
months. At CHOP from 1994-95 to 2005-06, the highest
monthly incidence of rotavirus gastroenteritis was
Table 2: Serotype of community-acquired rotavirus cases presenting to CHOP during the 6 rotavirus epidemic seasons 
(1999-2000 through 2005-06)§ prior to introduction of the new rotavirus vaccines◊ by age
0 to 5 months 6 to 11 months 12 to 17 months 18 to 23 months ≥2 years All Ages
n (%) n (%) n (%) n (%) n (%) n (%)
G1 134 (63) 182 (76) 112 (74) 90 (78) 154 (71) 672 (72)
G2 41 (19) 20 (9) 17 (11) 12 (10) 39 (18) 129 (14)
G3 3 (1) 6 (3) 5 (3) 0 (0) 3 (1) 17 (2)
G4 6 (3) 3 (1) 4 (3) 0 (0) 5 (2) 18 (2)
G8 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 1 (<1)
G9 24 (11) 15 (6) 8 (5) 7 (6) 13 (6) 67 (7)
G12 5 (2) 11 (5) 6 (4) 6 (5) 2 (1) 30 (3)
Totals (7 seasons) 213 (100) 238 (100) 152 (100) 115 (100) 216 (100) 934 (100)
n (%), number (percent) of cases in the specified age category infected with each identified rotavirus serotype.
§Starting with the 1999-2000 season, ELISA-positive specimens were genotyped by reverse transcriptase-polymerase chain reaction at Merck 
Research Laboratories when the quantity of stool specimen permitted (1, 33). Designation of G-serotype was based on nucleic acid homology 
in comparison with a database of sequences of known serotypes.
◊A tetravalent rotavirus vaccine had been transiently marketed in the United States in 1998-99.
Figure 2 A pie chart depicting the incidence of community-acquired rotavirus cases presenting to CHOP during the last 12 rotavirus epi-
demic seasons (1994-05 through 2005-06) prior to introduction of the new rotavirus vaccines. Each slice is identified by age grouping, number 
of cases in the specified age range, and percentage of cases in the specified age range.
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observed during the second month of life, by which time
levels of maternal antibody against rotavirus may have
substantially waned in many infants (25). Widespread
uptake of an effective rotavirus vaccine could reduce
maternal antibody levels by inducing herd immunity and
reducing adult infections. On the other hand, herd
immunity might serve to prevent infection in yet-to-be-
vaccinated infants. Rotavirus vaccines are usually given to
infants at ~2 months of age; even 1 dose of either the
monovalent (RV1) or pentavalent (RV5) vaccine likely
affords some protection against severe disease within 2
weeks of administration bridging the gap until the next
dose. Subsequent to the introduction of the new rotavirus
vaccines, the relative frequencies of cases in children both
younger than 6 months and older than 2 years have
increased at CHOP (1). Infants in the first few months of
life may remain vulnerable to serious rotavirus infections
and constitute a sizeable fraction of the cases seen at
CHOP. Our findings should prompt a possible rethinking
of the optimal rotavirus immunization schedule in order
to safely and effectively balance the heretofore underap-
preciated susceptibility of newborns with concerns about
suboptimal vaccine responses in the presence of maternal
antibodies (28, 39-46).
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